van Puijenbroek, Eugène https://orcid.org/0000-0002-2236-1398
Barry, Abbie
Khaemba, Christabel https://orcid.org/0000-0003-0543-9920
Ntirenganya, Lazare
Gebreyesus, Tigist Dires https://orcid.org/0000-0002-8969-9916
Fimbo, Adam https://orcid.org/0000-0002-9356-2218
Minzi, Omary https://orcid.org/0000-0001-8692-1924
Makonnen, Eyasu https://orcid.org/0000-0002-9259-5288
Oluka, Margaret https://orcid.org/0000-0002-4881-8667
Guantai, Anastasia
Aklillu, Eleni https://orcid.org/0000-0002-9788-0790
Funding for this research was provided by:
European and Developing Countries Clinical Trials Partnership (EDCTP) 2 (CSA2016S-1618)
Article History
Accepted: 16 July 2024
First Online: 20 August 2024
Declarations
:
: This short-term training was part of the “Pharmacovigilance infrastructure and post-marketing surveillance system capacity building for regional medicine regulatory harmonization in East Africa” (PROFORMA) project supported by the European and Developing Countries Clinical Trials Partnership (EDCTP) 2 programme supported by the European Union (grant number CSA2016S-1618).
: Eugène van Puijenbroek is an Editorial Board member of <i>Drug Safety</i>. Eugène van Puijenbroek was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. All other authors declare no relevant conflicts of interest relevant to this article.
: Not applicable.
: Not applicable.
: Not applicable.
: The code of the e-learning modules developed is not available.
: Not Applicable.
: The design of the manuscript was determined by EvP. The baseline assessment was conducted by AB. Views from academic institutions and national medicines regulatory authorities were provided by AB, CK, LN, TDG, AF, OM, EM, MO, AG and EL. All authors contributed to manuscript drafting and revision. All authors approved the final version to be published and agreed to be accountable for all aspects of the work.